These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36069490)

  • 21. Effects of gadolinium contrast agent administration on automatic brain tissue classification of patients with multiple sclerosis.
    Warntjes JB; Tisell A; Landtblom AM; Lundberg P
    AJNR Am J Neuroradiol; 2014 Jul; 35(7):1330-6. PubMed ID: 24699093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.
    Kappos L; Moeri D; Radue EW; Schoetzau A; Schweikert K; Barkhof F; Miller D; Guttmann CR; Weiner HL; Gasperini C; Filippi M
    Lancet; 1999 Mar; 353(9157):964-9. PubMed ID: 10459905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Contrast agents in MRI-diagnosis of multiple sclerosis].
    Abakumova TO; Nukolova NV; Gusev EI; Chekhonin VP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):58-65. PubMed ID: 25909791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone.
    Krapf H; Mauch E; Fetzer U; Laufen H; Kornhuber HH
    Neuroradiology; 1995 Feb; 37(2):113-9. PubMed ID: 7760994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.
    Lie IA; Kerklingh E; Wesnes K; van Nederpelt DR; Brouwer I; Torkildsen Ø; Myhr KM; Barkhof F; Bø L; Vrenken H
    Eur Radiol; 2022 May; 32(5):3576-3587. PubMed ID: 34978580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis.
    Rovira A; Auger C; Huerga E; Corral JF; Mitjana R; Sastre-Garriga J; Tintoré M; Montalban X
    AJNR Am J Neuroradiol; 2017 Aug; 38(8):1486-1493. PubMed ID: 28619842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrast enhanced magnetic resonance imaging of the brain using gadolinium-DTPA.
    Valk J; de Slegte RG; Crezee FC; Hazenberg GJ; Thjaha SI; Nauta JJ
    Acta Radiol; 1987; 28(6):659-65. PubMed ID: 2962597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of central veins and susceptibility weighted imaging for evaluating lesions in multiple sclerosis and leukoaraiosis.
    Lamot U; Avsenik J; Šega S; Šurlan Popovič K
    Mult Scler Relat Disord; 2017 Apr; 13():67-72. PubMed ID: 28427705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signal Hyperintensity on Unenhanced T1-Weighted Brain and Cervical Spinal Cord MR Images after Multiple Doses of Linear Gadolinium-Based Contrast Agent.
    Barisano G; Bigjahan B; Metting S; Cen S; Amezcua L; Lerner A; Toga AW; Law M
    AJNR Am J Neuroradiol; 2019 Aug; 40(8):1274-1281. PubMed ID: 31345942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gadolinium should always be used to assess disease activity in MS - No.
    Rovira À; Wattjes MP
    Mult Scler; 2020 Jun; 26(7):767-769. PubMed ID: 32484010
    [No Abstract]   [Full Text] [Related]  

  • 31. Gadolinium-Enhanced Susceptibility-Weighted Imaging in Multiple Sclerosis: Optimizing the Recognition of Active Plaques for Different MR Imaging Sequences.
    do Amaral LLF; Fragoso DC; Nunes RH; Littig IA; da Rocha AJ
    AJNR Am J Neuroradiol; 2019 Apr; 40(4):614-619. PubMed ID: 30846435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE ΔT1 mapping.
    Choi S; Spini M; Hua J; Harrison DM
    PLoS One; 2021; 16(4):e0249973. PubMed ID: 33901207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics.
    Saade C; Bou-Fakhredin R; Yousem DM; Asmar K; Naffaa L; El-Merhi F
    AJNR Am J Neuroradiol; 2018 Dec; 39(12):2168-2176. PubMed ID: 30385472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gadolinium should always be used to assess disease activity in MS - Yes.
    Granziera C; Reich DS
    Mult Scler; 2020 Jun; 26(7):765-766. PubMed ID: 32484018
    [No Abstract]   [Full Text] [Related]  

  • 35. Routine Gadolinium Use for MRI Follow-Up of Multiple Sclerosis: Point-The Role of Leptomeningeal Enhancement.
    Okar SV; Reich DS
    AJR Am J Roentgenol; 2022 Jul; 219(1):24-25. PubMed ID: 34786959
    [No Abstract]   [Full Text] [Related]  

  • 36. Fat-saturated post gadolinium T1 imaging of the brain in multiple sclerosis.
    Al-Saeed O; Ismail M; Athyal R; Sheikh M
    Acta Radiol; 2011 Jun; 52(5):570-4. PubMed ID: 21498296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial for "Relationship Between Simulated Gadolinium-Based Contrast Agent Injection Profile and Achievable Resolution Metrics in Contrast-Enhanced Magnetic Resonance Angiography".
    Roditi G
    J Magn Reson Imaging; 2022 Jun; 55(6):1808-1809. PubMed ID: 34726303
    [No Abstract]   [Full Text] [Related]  

  • 38. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions.
    van Waesberghe JH; Castelijns JA; Roser W; Silver N; Yousry T; Lycklama à Nijeholt GJ; Adèr HJ; Uitdehaag BM; Radue EW; Polman CH; Kappos L; Miller DH; Barkhof F
    AJNR Am J Neuroradiol; 1997 Aug; 18(7):1279-85. PubMed ID: 9282855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging.
    Tourdias T; Roggerone S; Filippi M; Kanagaki M; Rovaris M; Miller DH; Petry KG; Brochet B; Pruvo JP; Radüe EW; Dousset V
    Radiology; 2012 Jul; 264(1):225-33. PubMed ID: 22723563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Magnetic resonance tomography with gadolinium DTPA in multiple sclerosis. Findings in initial manifestation and later disease stages].
    Rüttinger H; Hermes M
    Nervenarzt; 1990 Jun; 61(6):356-60. PubMed ID: 2377261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.